Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.